Journal article

A comprehensive evaluation of interaction between genetic variants and use of menopausal hormone therapy on mammographic density

Anja Rudolph, Peter A Fasching, Sabine Behrens, Ursula Eilber, Manjeet K Bolla, Qin Wang, Deborah Thompson, Kamila Czene, Judith S Brand, Jingmei Li, Christopher Scott, V Shane Pankratz, Kathleen Brandt, Emily Hallberg, Janet E Olson, Adam Lee, Matthias W Beckmann, Arif B Ekici, Lothar Haeberle, Gertraud Maskarinec Show all

Breast Cancer Research | BIOMED CENTRAL LTD | Published : 2015

Grants

Awarded by European Community's Seventh Framework Programme (COGS)


Awarded by Cancer Research UK


Awarded by National Institutes of Health


Awarded by Post-Cancer GWAS initiative - the GAME-ON initiative


Awarded by Department of Defence


Awarded by National Cancer Institute (USA)


Awarded by NIH


Awarded by NIH Specialized Program of Research Excellence (SPORE) in Breast Cancer


Awarded by Australian NHMRC


Awarded by National Cancer Institute within the National Institutes of Health


Awarded by Medical Research Council


Awarded by National Institute for Health Research


Funding Acknowledgements

Names of the approving ethical committees are as follows: ABCFS, The University of Melbourne and The Cancer Councils of Victoria and New South Wales; BBCC, Ethics Committee of the Friedrich-Alexander-University Erlangen-Nuremberg; EPIC: Norwich Local Research Ethics Committee; MCBCS, Mayo Institutional Review Board; MCCS, The Cancer Council Victoria's Human Research Ethics Committee; MEC, Institutional Review Boards of the University of Hawaii and University of Southern California; MMHS, Mayo Institutional Review Board; OFBCR, Mount Sinai Hospital Research Ethics Board; SASBAC, Regionala Etikprovningsnamnden i Stockholm (Regional Ethical Review Board in Stockholm); SIBS, Eastern Multicentre Research Ethics Committee; BCAC/COGS, this study would not have been possible without the contributions of the following: Andrew Lee, and Ed Dicks, Craig Luccarini and the staff of the Centre for Genetic Epidemiology Laboratory, Javier Benitez, Anna Gonzalez-Neira and the staff of the CNIO genotyping unit, Jacques Simard and Daniel C. Tessier, Francois Bacot, Daniel Vincent, Sylvie LaBoissiere and Frederic Robidoux and the staff of the McGill University and Genome Quebec Innovation Centre, Stig E. Bojesen, Sune F. Nielsen, Borge G. Nordestgaard, and the staff of the Copenhagen DNA laboratory, and Julie M. Cunningham, Sharon A. Windebank, Christopher A. Hilker, Jeffrey Meyer and the staff of Mayo Clinic Genotyping Core Facility. Funding for the iCOGS infrastructure came from: the European Community's Seventh Framework Programme under grant agreement no 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 - the GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund. ABCFS would like to thank Maggie Angelakos, Judi Maskiell, and Gillian Dite. The ABCFS was supported by grant UM1 CA164920 from the National Cancer Institute (USA). The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the USA Government or the BCFR. The ABCFS was also supported by the National Health and Medical Research Council of Australia, the New South Wales Cancer Council, the Victorian Health Promotion Foundation (Australia) and the Victorian Breast Cancer Research Consortium. JLH is a National Health and Medical Research Council (NHMRC) Australia Fellow and a Victorian Breast Cancer Research Consortium Group Leader. MCS is a NHMRC Senior Research Fellow and a Victorian Breast Cancer Research Consortium Group Leader. The work of the BBCC was partly funded by ELAN-Fond of the University Hospital of Erlangen. EPIC-Norfolk was funded by research program grant funding from Cancer Research UK and the Medical Research Council with additional support from the Stroke Association, British Heart Foundation, Department of Health, Research into Ageing and Academy of Medical Sciences.The MCBCS was supported by the NIH grants CA128978, CA116167, CA176785 an NIH Specialized Program of Research Excellence (SPORE) in Breast Cancer [CA116201], and the Breast Cancer Research Foundation and a generous gift from the David F. and Margaret T. Grohne Family Foundation and the Ting Tsung and Wei Fong Chao Foundation. MCCS cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further supported by Australian NHMRC grants 209057, 251553 and 504711 and by infrastructure provided by Cancer Council Victoria. The MEC was supported by NIH grants CA63464, CA54281, CA098758 and CA132839. MMHS would like to acknowledge the participants within the Mayo Mammography Health Study, Ms. Fang Fang Wu for her review of all mammograms for the study and the Array Corporation, USA, for the donation of the digitizer that enabled this work. The MMHS work was supported by the National Cancer Institute within the National Institutes of Health (R01 CA128931, R01 CA140286, R01 CA97396, P50 CA116201, R01 CA177150). The Ontario Familial Breast Cancer Registry (OFBCR) was supported by grant UM1 CA164920 from the National Cancer Institute (USA). The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the USA Government or the BCFR. SASBAC thanks the Swedish Medical Research Counsel. SASBAC study was supported by funding from the Agency for Science, Technology and Research of Singapore (A*STAR), the US National Institute of Health (NIH) and the Susan G. Komen Breast Cancer Foundation. The SIBS study was supported by program grant C1287/A10118 and project grants from Cancer Research UK (grant numbers C1287/8459).